

The Royalty Rate Report 2013

A Comprehensive Assessment of Valuation in the Pharmaceutical Sector

Edited by Heather Cartwright

Foreword

Preface

Acknowledgements

Introduction

1

History

- 1.1 Royalties: In the Beginning
- 1.2 Mining and Petroleum
- 1.3 Royalties: Incentives and Disincentives
- 1.4 Royalties by Industry Sector

2

Thought Leadership

- 2.1 Deconstructing Deals – Benchmarks and Effective Royalties: The Benchmarking Challenge
- 2.2 Benchmarking Effective Royalties
- 2.3 Developing a New Methodology
- 2.4 Is the Biotech Industry Different from Mainstream Pharma in its Royalty Requirements?
- 2.5 Biotech Royalty Stacks
 - 2.5.1 Technology Royalty Stacks
 - 2.5.2 Offset Clauses in Royalty Stacks
- 2.6 The 25% Rule of Thumb: If Only It Was That Simple!
 - 2.6.1 What is the 25% Rule?
- 2.7 Overt or Covert
 - 2.7.1 Thoughts on Royalty Revelation

3

Benchmarking and eNPV

- 3.1 Methods for Calculating Royalties
- 3.2 Return of Research and Development Costs
- 3.3 Setting Royalties: The Tools
- 3.4 Benchmarking
- 3.5 Deal Benchmarking in Practice
- 3.6 Transfer Pricing: A Hidden Distortion to Royalties
- 3.7 Expected Net Present Value (eNPV)

3.8 The Basics of eNPV and NPV Calculation

- 3.8.1 Cash Flows
- 3.8.2 Relevant Costs
- 3.8.3 Real versus Nominal Figures
- 3.8.4 Opportunity Cost/Time Value

3.9 Risk

- 3.9.1 Decision Tree Analysis
- 3.10 A Further Refinement of the eNPV Model: Sensitivity Analysis
- 3.11 Development Cash Burn

4

Data and Trends

- 4.1 Disclosure of Royalties: Why the Big Secret?
- 4.2 Who Was That Masked Man?
- 4.3 Big Pharma Global Licensing
- 4.4 Top 15 Big Pharma Royalty Rate Disclosure Frequency
 - 4.4.1 Pfizer
 - 4.4.2 GlaxoSmithKline
 - 4.4.3 AstraZeneca
 - 4.4.4 Novartis
 - 4.4.5 Merck & Co.
- 4.5 Addressing Gaps in Agreements
- 4.6 Licensing Deals in Japan: Culture and Tax
- 4.7 Standard Terms: Exceptions to the Rule
- 4.8 Royalties and Deal Structures
 - 4.8.1 Sales Milestones: A Royalty by Any Other Name
 - 4.8.2 Combining Sales Milestones with Tiered Royalties
 - 4.8.3 Alternative Structures
 - 4.8.4 Tiered Royalties
- 4.9 How much Value Does the Royalty Component Constitute?
- 4.10 An Analysis of Rates Used in a Phase III Deal
- 4.11 Royalties in Early-Stage Technology Deals
- 4.12 Participation
- 4.13 Royalties to Fund Development Costs

- 4.14 Creativity: There's More Than One Way to Skin a Cat
- 4.15 Upfronts and Milestones: Are There Changes Afoot?
- 4.16 Royalty Rates by Phase and Indication
 - 4.16.1 Preclinical Deal Royalties
 - 4.16.2 Phase I Deal Royalties
 - 4.16.3 Phase II Deal Royalties
 - 4.16.4 Phase III Deal Royalties
 - 4.16.5 Preregistration/Registered/Approved Deal Royalties
 - 4.16.6 Launched Product Deal Royalties
- 4.17 Royalties and Generics: The Beginning of the End?
- 4.18 Royalties and IP Valuation
- 4.19 IP Value and Market Cap
- 4.20 Monetising the Royalty Stream
- 4.21 The Utility Cost of Cashing In: Jam Today or More Jam Tomorrow
- 4.22 The Current Economic Climate and its Effect on Royalty Rates

5

Industry Perceptions

- 5.1 Royalties: A Review of Recent Literature
- 5.2 Auditing the Pharma Royalty Market: 'Lies, Damned Lies, and Statistics'?
 - 5.2.1 PharmaDeals Survey 2013
 - 5.2.2 PharmaDeals Survey 2011
 - 5.2.3 Licensing Executives Society

Addendum

- A.1 Royalty Rate Deals Chart: 2004 – January 2013
- A.2 Drug 'X' Utility Cost: eNPV and Discount Rate Calculation
- A.3 Royalty Monetisers: Key Deals
 - A.3.1 DRI Capital
 - A.3.2 Paul Capital
 - A.3.3 Royalty Pharma
- A.4 Data from the 2013 PharmaDeals Deal Terms Survey
- A.5 Great Expectations: The 2011 Survey
 - A.5.1 Introduction to the 2011 Survey
 - A.5.2 Disclosure of Royalty Rates
 - A.5.3 Expected Minimum and Maximum Royalty Rates
 - A.5.4 Types of Licenses
 - A.5.5 Perceptions on Difficulties of Doing Deals
 - A.5.6 Licensor/licensee – Who is Favoured?
 - A.5.7 Trends for Upfront and Milestone Payments
 - A.5.8 Prevalence of commercial milestones
 - A.5.9 Tiered Royalty Rates
 - A.5.10 Royalties and Creativity
 - A.5.11 Royalties and Total Deal Values

Glossary of Terms